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Introduction
Myocardial oxygen consumption (MVO2) directly reflects
myocardial oxygen supply and demand. The purpose of
this study is to test the ability of a cardiovascular magnetic
resonance (CMR) method to determine changes in myo-
cardial MVO2 during pharmacologically-induced hypere-
mia in a canine stenosis model.
Methods
13 dogs were divided into four groups, which can be seen
in Table 1. Stenosis was created by an occluder around the
proximal left-anterior descending (LAD) and stenosis
severity was confirmed via Doppler flow reduction. MVO2
was calculated by the Fick principle: MVO2 ∝ OEF × MBF,
in which OEF is the oxygen extraction fraction and MBF
represents myocardial blood flow.
OEF during hyperemia was determined by a two compart-
ment model with measured myocardial T2 that is meas-
ured with a 2-D segmented turbo spin-echo (TSE)
sequence [1]. This sequence was performed several times
at rest and during either Dipyridamole-induced vasodila-
tion or Dobutamine-induced hyperemia. Rest OEF was
assumed to be 0.6, which is based on values measured in
normal dogs using an arterial and coronary sinus blood
sampling approach at rest [2]. MBF values, both at rest
and during pharmaceutical stress, were determined with
the quantitative first-pass perfusion CMR method. First-
pass images were denoised and MBF maps were created
with an algorithm that was developed and validated in
our laboratory [3]. MVO2 values were determined in the
stenotic LAD perfused anterior region and the remote left-
circumflex (LCX) perfused inferior region.
Results
MVO2 results can be seen in Figure 1. As expected, Dob-
utamine causes a dramatic increase in MVO2, while injec-
tion of Dipyridamole shows only a moderate effect.
In the anterior area with LAD stenosis, after the injection
of Dipyridamole, a small increase in MVO2 was observed
at 13.8% and 10.7% for the 70% and 90% stenosis
groups, respectively. With Dobutamine, MVO2 increased
significantly at 57.9% and 35% for the 50% and 70–90%
stenosis groups, respectively.
In the remote normal LCX perfused region, Dipyridamole
induced moderate increases in MVO2 at 49.9% and 17.3%
in the 70% and 90% stenosis groups, respectively. This is
different from conventional wisdom that Dipyridamole
would induce no changes in MVO2, but is consistent with
a report using adenosine injection in dogs [4]. As
expected, Dobutamine induced much higher changes in
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Table 1: Dog groups
Group (n) Stenosis Stress
1 (4) 70% Dipyridamole
2 (3) 90% Dipyridamole
3 (3) 50% Dobutamine
4 (3) 70–90% DobutaminePage 1 of 2
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MVO2, 183.7% and 79% increases in the 50% and
70–90% stenosis groups, respectively. It is interesting to
note that severe single-vessel stenosis not only attenuated
the increase in MVO2 in stenotic perfused region with
both Dipyridamole and Dobutamine, but also attenuated
MVO2 in the remote normal myocardial region.
Conclusion
Our CMR method can non-invasively quantify regional
myocardial MVO2. Determination of the changes in
MVO2 is important in the diagnosis and management of
patients with coronary artery disease.
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Changes in MVO2 during dipyridamole or dobutamine with various LAD stenosisFigur  1
Changes in MVO2 during dipyridamole or dobutamine with various LAD stenosis. A quantitative CMR method is introduced to 
detect changes in myocardial MVO2 during hyperemia in a canine stenosis model. While severe stenosis attenuated MVO2 
increase in the stenosis subtended region, the remote region also showed reduced increase in MVO2.Page 2 of 2
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